Abstract
Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Current Pharmaceutical Design
Title:GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Volume: 21 Issue: 34
Author(s): Carlos Alberto Yasin Wayhs, Helena Maria Tannhauser Barros and Carmen Regla Vargas
Affiliation:
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Abstract: Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Export Options
About this article
Cite this article as:
Wayhs Alberto Yasin Carlos, Barros Maria Tannhauser Helena and Vargas Regla Carmen, GABAergic Modulation in Diabetic Encephalopathy-Related Depression, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150914121331
DOI https://dx.doi.org/10.2174/1381612821666150914121331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology An Insight Into the Anxiolytic Effects of Lignans (Phyllanthin and Hypophyllanthin) and Tannin (Corilagin) Rich Extracts of <i>Phyllanthus amarus</i> : An <i>In-Silico</i> and <i>In-vivo</i> approaches
Combinatorial Chemistry & High Throughput Screening Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs
Current Clinical Pharmacology Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Vaccine Safety Monitoring Systems in Developing Countries: An Example of the Vietnam Model
Current Drug Safety Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Current Drug Targets Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design <i>In Vivo</i> Longitudinal Monitoring of Changes in the Corpus Callosum Integrity During Disease Progression in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets